Most Read Articles
3 days ago
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
6 days ago
A recent study has shown that the herpes zoster (HZ) vaccine induces varicella zoster virus (VZV)-specific cellular and humoral responses in patients with rheumatic arthritis (RA).
4 days ago
Compared to other tumour necrosis factor–α inhibitors (TNFi), infliximab remains superior in reducing Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at 12 weeks, results of a network meta-analysis (NMA) have shown. However, it was sensitive to inclusion of an open-label trial, and its efficacy faded at 24 weeks.

Systemic sclerosis-related pulmonary hypertension in an era of new therapies

07 Mar 2017
At the 17th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
6 days ago
A recent study has shown that the herpes zoster (HZ) vaccine induces varicella zoster virus (VZV)-specific cellular and humoral responses in patients with rheumatic arthritis (RA).
4 days ago
Compared to other tumour necrosis factor–α inhibitors (TNFi), infliximab remains superior in reducing Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at 12 weeks, results of a network meta-analysis (NMA) have shown. However, it was sensitive to inclusion of an open-label trial, and its efficacy faded at 24 weeks.